Galati Domenico, Zanotta Serena
Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 49, 80131 Naples, Italy.
Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola 49, 80131 Naples, Italy.
Clin Immunol. 2017 Oct;183:181-190. doi: 10.1016/j.clim.2017.08.016. Epub 2017 Sep 12.
Dendritic cells (DCs) are bone-marrow-derived immune cells accounted for a key role in cancer vaccination as potent antigen-presenting cells within the immune system. Cancer microenvironment can modulate DCs maturation resulting in their accumulation into functional states associated with a reduced antitumor immune response. In this regard, a successful cancer vaccine needs to mount a potent antitumor immune response able to overcome the immunosuppressive tumor milieu. As a consequence, DCs-based approaches are a safe and promising strategy for improving the therapeutic efficacy in hematological malignancies, particularly in combinations with additional treatments. This review summarizes the most significant evidence about the immunotherapeutic strategies performed to target hematologic neoplasms including the tumoral associated antigens (TAA) pulsed on DCs, whole tumor cell vaccines or leukemia-derived DCs.
树突状细胞（DCs）是源自骨髓的免疫细胞，作为免疫系统中强大的抗原呈递细胞，在癌症疫苗接种中发挥关键作用。癌症微环境可调节DCs的成熟，导致其积累到与抗肿瘤免疫反应降低相关的功能状态。在这方面，成功的癌症疫苗需要引发强大的抗肿瘤免疫反应，以克服免疫抑制性肿瘤微环境。因此，基于DCs的方法是提高血液系统恶性肿瘤治疗效果的一种安全且有前景的策略，特别是与其他治疗方法联合使用时。本综述总结了针对血液系统肿瘤所采用的免疫治疗策略的最重要证据，包括负载于DCs上的肿瘤相关抗原（TAA）、全肿瘤细胞疫苗或白血病衍生的DCs。
